Anticancer agents and cardiotoxicity
- PMID: 16473642
- DOI: 10.1053/j.seminoncol.2005.11.001
Anticancer agents and cardiotoxicity
Abstract
Although rare, cardiotoxicity is a significant complication of cancer treatment. The incidence and severity of cardiotoxicity are dependent on the type of drugs used, dose and schedule employed, and age of patients, as well as the presence of coexisting cardiac diseases and previous mediastinal irradiation. Anthracyclines are among one of the most active agents in oncology, but their use is often hampered by their cumulative dose-limiting cardiotoxicity. Combination therapy with new drugs in the last decade, such as taxanes and trastuzumab, in the treatment of metastatic breast cancer has yielded impressive results but also unexpected cardiotoxicity. Existing methods of minimizing cardiotoxicity include the use of protective agents such as dexrazoxane, different preparations of anthracyclines such as liposomal formulations, and alternative scheduling techniques. Assessment of left ventricular ejection fraction (LVEF) with two-dimensional (2D)-echocardiography or radionuclide ventriculography (RNVG) remains the most pragmatic means of monitoring for cardiotoxicity. The increasing number of long-term survivors of pediatric cancers, as well as the use of trastuzumab, taxanes, and anthracyclines in adjuvant treatment of breast cancer, means that more than ever, cardiotoxicity will remain an important issue for clinicians.
Similar articles
-
Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.Semin Oncol. 2006 Jun;33(3 Suppl 8):S15-21. doi: 10.1053/j.seminoncol.2006.04.022. Semin Oncol. 2006. PMID: 16781285 Review.
-
[Cardiotoxicity of drugs used in oncology].Klin Onkol. 2008;21(5):288-93. Klin Onkol. 2008. PMID: 19202960 Review. Czech.
-
Overview and historical development of dexrazoxane.Semin Oncol. 1998 Aug;25(4 Suppl 10):48-54. Semin Oncol. 1998. PMID: 9768824 Review.
-
[Risk of cardiotoxicity of combination treatment radiotherapy and chemotherapy of locally advanced breast carcinoma stage III].Klin Onkol. 2009;22(1):17-21. Klin Onkol. 2009. PMID: 19534435 Czech.
-
Ameliorating anthracycline cardiotoxicity in children with cancer: clinical trials with dexrazoxane.Semin Oncol. 1998 Aug;25(4 Suppl 10):86-92. Semin Oncol. 1998. PMID: 9768829 Review.
Cited by
-
Is Electrocardiogram Helpful in Predicting a Rise in Troponin I as a Marker of Anthracycline Cardiotoxicity?Eur J Breast Health. 2022 Oct 1;18(4):299-305. doi: 10.4274/ejbh.galenos.2022.2021-9-8. eCollection 2022 Oct. Eur J Breast Health. 2022. PMID: 36248753 Free PMC article.
-
Successful recovery and allogeneic stem cell transplant following chemotherapy-induced severe cardiomyopathy: literature review of management and prognostic factors.BMJ Case Rep. 2016 Nov 16;2016:bcr2016217210. doi: 10.1136/bcr-2016-217210. BMJ Case Rep. 2016. PMID: 27852680 Free PMC article. Review.
-
Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review.Oncologist. 2010;15(3):216-35. doi: 10.1634/theoncologist.2009-0145. Epub 2010 Mar 3. Oncologist. 2010. PMID: 20200040 Free PMC article. Review.
-
Plitidepsin has a safe cardiac profile: a comprehensive analysis.Mar Drugs. 2011;9(6):1007-1023. doi: 10.3390/md9061007. Epub 2011 Jun 9. Mar Drugs. 2011. PMID: 21747745 Free PMC article. Clinical Trial.
-
Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction.Am Heart J. 2012 Dec;164(6):846-55. doi: 10.1016/j.ahj.2012.09.001. Epub 2012 Oct 26. Am Heart J. 2012. PMID: 23194484 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical